Published in J Thorac Oncol on December 01, 2011
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther (2011) 1.57
Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol (2013) 0.98
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol (2015) 0.90
Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer (2013) 0.88
Crizotinib: A comprehensive review. South Asian J Cancer (2013) 0.85
Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics (2013) 0.80
Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). Cancer Med (2016) 0.78
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol (2015) 0.76
Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity. Cardiooncology (2017) 0.75
Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects. Arq Bras Cardiol (2014) 0.75
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A (2006) 2.01
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol (2014) 1.41
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol (2014) 1.02
Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer (2013) 1.00
Ryanodine receptors in muscarinic receptor-mediated bronchoconstriction. J Biol Chem (2005) 0.99
Dynamic regulation of sarcoplasmic reticulum Ca(2+) stores by stromal interaction molecule 1 and sarcolipin during muscle differentiation. Dev Dyn (2012) 0.90
Excitation-contraction coupling in airway smooth muscle. J Biol Chem (2006) 0.90
Effect of oxidative stress on homer scaffolding proteins. PLoS One (2011) 0.77